Abiogen, EffRx, Atral, Lacer S.A. sales and marketing update

EffRx granted distribution and commercialization rights for Binosto alendronate to Abiogen in Italy, Lacer in Spain and Atral in Portugal. The alendronate effervescent is approved in the U.S., EU and Australia to treat osteoporosis. EffRx expects its partners to launch Binosto in Italy, Spain and Portugal next quarter. EffRx said it received undisclosed upfront payments and will not be eligible for royalties on net sales, but declined to disclose further terms. Lacer and Atral declined to disclose financial terms, and Abiogen could not be reached. ...